Quintrio
Home

PHARMACEUTICAL PREPARATIONS

Cellectar Biosciences INC NEW

CLRB

Cellectar Biosciences Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of drugs for the treatment of cancer. The company's core objective is to leverage a proprietary phospholipid drug conjugate (PDC) delivery platform to develop PDCs that are designed to specifically target cancer cells and deliver improved efficacy and safety as a result of fewer off-target effects. The products under development include Iopofosine, CLR 121125 ,CLR 121225 and others. It has one operating and reportable segment focused on utilizing its PDC platform to develop drugs for the treatment of cancer.

Last trade $0.92
Day change -$0.09 (-8.91%)
Day range $0.905 – $1.06
Volume 59,717
Market cap $10M

Open XNAS

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

Valuation

Market capitalization
$10.14M
Price / earnings
—
Price / book
0.45×
Price / sales
—
EV / sales
—
EV / EBITDA
0.54×

Profitability

Earnings per share
-$2.58
Return on assets
-86.93%
Return on equity
-115.34%
Dividend yield
0%

Liquidity and leverage

Debt / equity
0×
Current ratio
4.44×
Quick ratio
4.44×
Cash ratio
4.24×

Cash flow

Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$24.62M

Ratios use trailing-twelve-month financials and market data as of Nov 16, 2026.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

Income statement for CLRB, quarterly periods
Line itemQ3 FY2026 Sep 30, 2026Q2 FY2026 Jun 30, 2026Q1 FY2026 Mar 31, 2026Q4 FY2025 Dec 31, 2025Q3 FY2025 Sep 30, 2025Q2 FY2025 Jun 30, 2025Q1 FY2025 Mar 31, 2025Q4 FY2024 Dec 31, 2024
Revenue$0$0$0$0$0$0$0$0
Cost of revenue$0$0$0$0$0$0$0$0
Gross profit$0$0$0$0$0$0$0$0
Selling, general and administrative$2.67M$2.64M$2.79M$2.53M$2.33M$3.65M$2.97M$6.54M
Research and development$5.44M$4.56M$3.01M$3.16M$2.52M$2.39M$3.43M$6.21M
Total operating expenses$8.1M$7.2M$5.79M$5.69M$4.85M$6.04M$6.4M$20.49M
Operating income-$8.1M-$7.2M-$5.79M-$5.69M-$4.85M-$6.04M-$6.4M-$20.49M
Interest expense$179.27K$0$63K$0$112.54K$0$136.96K$0
Income before taxes-$7.97M-$6.93M-$5.65M-$5.3M-$4.44M-$5.45M-$6.6M-$2.29M
Income taxes$0$0$0$0$0$0$0$66K
Net income-$7.97M-$6.93M-$5.65M-$5.3M-$4.44M-$5.45M-$6.6M-$2.36M
Net income attributable to common shareholders-$7.97M-$6.93M-$5.65M-$5.3M-$4.44M-$5.45M-$6.6M-$2.36M
EBITDA-$8.07M-$7.16M-$5.9M-$5.64M-$4.8M-$5.98M-$6.34M-$20.42M
Basic earnings per share-$0.46-$0.57-$1.33-$1.28-$1.41-$3.39-$4.30-$1.68
Diluted earnings per share-$0.46-$0.57-$1.33-$1.28-$1.41-$3.39-$4.30-$1.68

Recent news

Company coverage with links to the original publishers.

Publication times in UTC

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily

No declared upcoming dividend found.

No prior dividend records found.

Stock splits

Historical share-structure events and their execution dates.

Updated daily
Execution dateSplit ratioEvent type
Jun 24, 20251-for-30reverse split
Jul 22, 20221-for-10reverse split
Jul 17, 20181-for-10reverse split
Mar 7, 20161-for-10reverse split
Jun 16, 20141-for-20reverse split
Jun 13, 20054-for-1forward split